


# R&D Pipeline – New Molecular Entities(\*)

Pipeline charts as communicated at  
Q4 and Full Year 2019 Results  
Meeting dated February 6, 2020



# Additional Indications(\*)

Pipeline charts as communicated at  
Q4 and Full Year 2019 Results  
Meeting dated February 6, 2020

Phase 1 (Total : 7)		Phase 2 (Total : 17)		Phase 3 (Total : 26)		Registration (Total : 3)	
SAR439459 + cemiplimab <sup>(*)</sup> Advanced Solid Tumors	dupilumab <sup>(*)</sup> Grass pollen allergy	isatuximab + cemiplimab <sup>(*)</sup> Relapsed Refractory MM	Dupixent <sup>®</sup> <sup>(*)</sup> Asthma 6 - 11 years old	isatuximab Newly Diag. MM Te <sup>(9)</sup> (GMMG)	Fluzone <sup>®</sup> QIV HD Influenza vaccine - High dose (EU)		
<b>O</b> cemiplimab <sup>(*)</sup> + REGN4018 <sup>(*)</sup> Ovarian Cancer	<b>R</b> sarilumab <sup>(*)</sup> Polyarticular Juvenile Idiopathic Arthritis	isatuximab + cemiplimab <sup>(*)</sup> Lymphoma	dupilumab <sup>(*)</sup> Eosinophilic Esophagitis	isatuximab 2L RRM (IKEMA)	MenQuadfi <sup>TM</sup> U.S. 2y+ , EU 1y+		
SAR439859 + palbociclib <sup>(9)</sup> Metastatic Breast Cancer	<b>R</b> sarilumab <sup>(*)</sup> Systemic Juvenile Arthritis	isatuximab + atezolizumab <sup>(7)</sup> mCRC	Dupixent <sup>®</sup> <sup>(*)</sup> AD 6 months - 5 years old	isatuximab 1L Newly Diag. MM Ti <sup>(10)</sup> (IMROZ)	Dupixent <sup>®</sup> <sup>(*)</sup> AD 6 – 11 years old (U.S., EU)		
sutimlimab Immune Thrombocytopenic Purpura	SAR440340 <sup>(*)</sup> COPD	isatuximab + atezolizumab <sup>(7)</sup> Solid Tumors	dupilumab <sup>(*)</sup> COPD	Aubagio <sup>®</sup> Relapsing MS – Pediatric			
SAR443060 <sup>(*)</sup> Multiple sclerosis	dupilumab <sup>(*)</sup> Peanut Allergy - Pediatric	venglustat Fabry Disease	dupilumab <sup>(*)</sup> Bullous pemphigoid	Lemtrada <sup>®</sup> Relapsing Remitting MS - Pediatric			
SAR442720 <sup>(*)</sup> + cobimetinib Relapsed Refractory solid tumors	SAR440340 <sup>(*)</sup> Asthma	venglustat Gaucher Type 3	dupilumab <sup>(*)</sup> Chronic spontaneous urticaria	Cerdelga <sup>®</sup> Gaucher T1, ERT switch Pediatric			
SAR441000 <sup>(*)</sup> + PD-1 Solid tumors	<b>R</b> cemiplimab <sup>(*)</sup> 2-L Basal Cell Carcinoma	venglustat GBA-PD <sup>(8)</sup>	dupilumab <sup>(*)</sup> Prurigo nodularis	Praluent <sup>®</sup> <sup>(*)</sup> LDL-C reduction - Pediatric			
	isatuximab 1-2L AML / ALL pediatrics	SP0173 Tdap booster US	sarilumab <sup>(*)</sup> Giant Cell Arteritis	Praluent <sup>®</sup> <sup>(*)</sup> LDL-C reduction – HoFH			
	SAR439859 Breast Cancer adjuvant		sarilumab <sup>(*)</sup> Polymyalgia Rheumatica	MenQuadfi <sup>TM</sup> 6w+ (US / EU)			
			cemiplimab <sup>(*)</sup> 1L NSCLC	Pediatric pentavalent vaccine <sup>(*)</sup> Japan			
			cemiplimab <sup>(*)</sup> + chemotherapy 1L NSCLC	Shan 6 Pediatric hexavalent vaccine			
			cemiplimab <sup>(*)</sup> 2L Cervical Cancer	VerorabVax <sup>®</sup> (VRVg) Purified vero rabies vaccine			
			cemiplimab <sup>(*)</sup> adjuvant in CSCC	fitusiran Hemophilia A and B pediatric			

**R** Registrational study (other than Phase 3)

**O** Opt-in rights products for which rights have not been exercised yet

(1) Developed in collaboration with Regeneron  
(2) Regeneron product for which Sanofi has opt-in rights  
(3) Pfizer product (palbociclib)  
(4) Developed in collaboration with Denali  
(5) Developed in collaboration with Revolution Medicines - cobimetinib is a Genentech product  
(6) Phase of projects determined by clinicaltrials.gov disclosure timing when relevant  
(\*\*) Partnered and/or in collaboration - Sanofi may have limited or shared rights on some of these products  
COPD = chronic obstructive pulmonary disease; AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia;  
MM = multiple myeloma;; R RMS = Relapsing / Remitting Multiple Sclerosis

Developed in collaboration with BioNTech  
Studies in collaboration with Genentech Inc. (atezolizumab)  
Parkinson's Disease with an associated GBA mutation  
Transplant eligible  
Transplant ineligible  
Developed in collaboration with Kitasato and Daiichi Sankyo (KDSV)

- Immuno-inflammation
- Oncology
- Rare Diseases
- Rare Blood Disorders
- MS & Neuro
- Diabetes
- Cardiovascular & metabolism
- Vaccines

# Pipeline movements since Q3 2019

Pipeline charts as communicated at  
Q4 and Full Year 2019 Results  
Meeting dated February 6, 2020

	Additions / Moves		Removals from Sanofi pipeline
Registration	<b>Dupixent<sup>®</sup>(**)(1)</b> AD 6 – 11 years old (U.S., EU)		
Phase 3	<b>BIVV001<sup>(**)(2)</sup></b> rFVIII Fc – vWF – XTEN <sup>(3)</sup> Hemophilia A		
	<b>SAR408701</b> Maytansin-loaded anti-CEACAM5 mAb, NSCLC 2/3L	<b>dupilumab<sup>(**)(1)</sup></b> Chronic spontaneous urticaria	
	<b>dupilumab<sup>(**)(1)</sup></b> Bullous pemphigoid	<b>dupilumab<sup>(**)(1)</sup></b> Prurigo nodularis	
Phase 2	<b>SAR439859</b> SERD Metastatic Breast Cancer 2/3L	<b>SAR439859</b> Breast Cancer adjuvant	<b>HIV</b> Viral vector prime & rgp120 boost vaccine
Phase 1	<b>SAR441000<sup>(**)(4)</sup> + PD-1</b> Solid tumors	<b>Yellow Fever</b> Vaccine (Vero cell)	
	<b>THOR-707</b> Non-alpha IL-2 Solid tumors		

(1) Developed in collaboration with Regeneron

(2) Developed in collaboration with Sobi

(3) Recombinant Coagulation Factor VIII Fc – von Willebrand Factor – XTEN Fusion protein

(4) Developed in collaboration with BioNTech

(\*\*) Partnered and/or in collaboration – Sanofi may have limited or shared rights on some of these products